Summary
Dietary Supplements is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Dietary Supplements to ME/CFS: 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Early Phase 1 (NCT06235177, sponsored by The Essence of Integrative Health and Medicine Practice). It plans or enrolled 30 participants. Registered activity dates to 2024. The literature layer holds 6 publications for this pair: 6 PubMed search records. Publication years run from 1993 to 2026. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 191 candidate agents are logged for ME/CFS, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 12.5 (trials 1.5, literature 6.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 1 other |
| Linked publications | 6 (6 PubMed search records) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not recorded |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06235177 | Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues The Essence of Integrative Health and Medicine Practice · 2024 | status unknown | Early Phase 1 | 30 |
Published literature
- PubMed record (biomarker-intervention search) The impact of personalized nutritional intake on serum inflammation, immune markers, and recovery time in patients with herpes zoster.BMC infectious diseases · 2026 · PMID 42350981
- PubMed record (biomarker-intervention search) Dance and Dietary Intervention Improves Metabolic Health, Fitness, and Quality of Life With Modest Gut Microbiota Shifts in Breast Cancer Patients With Obesity: A Pilot RCT.Cancer reports (Hoboken, N.J.) · 2026 · PMID 42321999
- PubMed record (biomarker-intervention search) Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial.Trials · 2026 · PMID 42271514
- PubMed record (biomarker-intervention search) Objective assessment of physical activity using wearable devices in patients with mild-to-moderate Crohn's disease.Journal of the Canadian Association of Gastroenterology · 2026 · PMID 42244848
- PubMed record (biomarker-intervention search) Sucrase-Isomaltase Deficiency in Children with Functional Gastrointestinal Disorders.Journal of clinical medicine · 2026 · PMID 42194600
- PubMed record (biomarker-intervention search) Glutaric Acidemia Type 1.1993 · PMID 31536184
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
Clinical notes: Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Dietary Supplements approved for ME/CFS?
Dietary Supplements is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Dietary Supplements in clinical trials for ME/CFS?
ClinicalTrials.gov lists 1 registered trial linking Dietary Supplements to ME/CFS: 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Early Phase 1 (NCT06235177, sponsored by The Essence of Integrative Health and Medicine Practice). It plans or enrolled 30 participants. Registered activity dates to 2024.
What does the evidence show for Dietary Supplements in ME/CFS?
Trials of Dietary Supplements in ME/CFS are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.